- Home
- MNOV vs INCR Comparison
MNOV vs INCR Comparison
Compare MNOV & INCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNOV
- INCR
- Stock Information
- Founded
- MNOV 2000
- INCR 1994
- Country
- MNOV United States
- INCR Israel
- Employees
- MNOV N/A
- INCR N/A
- Industry
- MNOV Biotechnology: Pharmaceutical Preparations
- INCR Biotechnology: Pharmaceutical Preparations
- Sector
- MNOV Health Care
- INCR Health Care
- Exchange
- MNOV Nasdaq
- INCR Nasdaq
- Market Cap
- MNOV 76.0M
- INCR 76.7M
- IPO Year
- MNOV 2005
- INCR N/A
- Fundamental
- Price
- MNOV $1.49
- INCR $1.45
- Analyst Decision
- MNOV Strong Buy
- INCR
- Analyst Count
- MNOV 1
- INCR 0
- Target Price
- MNOV $9.00
- INCR N/A
- AVG Volume (30 Days)
- MNOV 14.9K
- INCR 16.7K
- Earning Date
- MNOV 05-08-2025
- INCR 04-29-2025
- Dividend Yield
- MNOV N/A
- INCR N/A
- EPS Growth
- MNOV N/A
- INCR N/A
- EPS
- MNOV N/A
- INCR N/A
- Revenue
- MNOV N/A
- INCR $72,420,918.00
- Revenue This Year
- MNOV N/A
- INCR N/A
- Revenue Next Year
- MNOV N/A
- INCR $39.30
- P/E Ratio
- MNOV N/A
- INCR N/A
- Revenue Growth
- MNOV N/A
- INCR N/A
- 52 Week Low
- MNOV $1.12
- INCR $1.17
- 52 Week High
- MNOV $2.55
- INCR $3.72
- Technical
- Relative Strength Index (RSI)
- MNOV 54.28
- INCR 56.61
- Support Level
- MNOV $1.36
- INCR $1.33
- Resistance Level
- MNOV $1.52
- INCR $1.31
- Average True Range (ATR)
- MNOV 0.10
- INCR 0.06
- MACD
- MNOV 0.03
- INCR 0.02
- Stochastic Oscillator
- MNOV 92.31
- INCR 88.46
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. The products are distributed to hospitals, pharmacies, research, and government organizations. The company has two segments namely: Cannabis segment and Biomed segment, out of which it derives maximum revenue from Cannabis segment.